Etomidate Dosage for Rapid Induction and Continuous Sedation
For rapid sequence intubation in adults and children over 10 years, administer etomidate 0.3 mg/kg IV over 30-60 seconds; for children undergoing short painful procedures, use 0.2 mg/kg IV after fentanyl; continuous infusion for sedation is not recommended due to adrenal suppression risks. 1
Adult Dosing for Rapid Sequence Intubation
The FDA-approved dosing range for induction is 0.2-0.6 mg/kg IV, with the standard dose being 0.3 mg/kg administered over 30-60 seconds 1. This dose provides rapid onset (within 1 minute) and brief duration (3-5 minutes) of anesthesia 1.
Dose Modifications in Special Populations
- Hemodynamically compromised patients: Consider reducing to 0.15 mg/kg based on trauma data 2
- Geriatric patients: Require reduced doses due to risk of decreased heart rate, cardiac index, and mean arterial pressure 1
- Critically ill patients: The 2023 Society of Critical Care Medicine guidelines suggest no difference between etomidate and other induction agents regarding mortality or hypotension, supporting standard 0.2-0.3 mg/kg dosing 2
Important caveat: While a 2025 randomized trial of 2,365 critically ill adults found no mortality difference between ketamine and etomidate at 28 days, ketamine was associated with higher rates of cardiovascular collapse during intubation (22.1% vs 17.0%) 3. A separate 2022 trial showed improved Day 7 survival with ketamine but no Day 28 difference 4. These findings suggest etomidate remains a reasonable choice for RSI, particularly in hemodynamically unstable patients.
Pediatric Dosing
Children Over 10 Years
Use the same adult dosing: 0.3 mg/kg IV over 30-60 seconds 1
Children Under 10 Years
The FDA states there are inadequate data for children under 10 years for anesthesia induction, and such use is not recommended 1. However, research evidence supports off-label use:
- For short painful procedures (e.g., fracture reduction): 0.2 mg/kg IV after fentanyl 1 μg/kg provides effective sedation with manageable respiratory events 5
- Additional 0.1 mg/kg doses may be given if needed 5
- This regimen achieved 98.3% procedural success with median discharge-ready time of 21 minutes 5
Continuous Infusion: NOT RECOMMENDED
Continuous etomidate infusion should be avoided due to significant adrenal suppression concerns:
- Single bolus doses cause adrenocortical dysfunction lasting 6-8 hours, unresponsive to ACTH 1
- While one study showed dysfunction resolves within 12 hours after a single 0.3 mg/kg dose 6, continuous infusion prolongs this effect
- Historical data on continuous infusion (10-20 μg/kg/min) showed increased adverse reactions at higher doses 7
- The 2023 SCCM guidelines do not support continuous etomidate infusion for sedation 2
If Continuous Sedation Needed
Use alternative agents (propofol, midazolam, dexmedetomidine) rather than etomidate infusion. Etomidate should be reserved for single-dose induction only.
Administration Technique
- Inspect solution: Must be clear; discard if particulate matter present 1
- Injection speed: Over 30-60 seconds to minimize myoclonus (occurs in 6-13% of patients) 1, 8
- Premedication: Compatible with standard pre-anesthetic medications including fentanyl and atropine 1
- Pain on injection: Occurs in approximately 6% of patients 8
Key Clinical Considerations
Respiratory monitoring is essential: Expect slight PaCO2 elevation and potential oxygen desaturation (39% in pediatric studies) requiring brief interventions like oxygen supplementation, stimulation, or airway repositioning 1, 5. No patients in the pediatric study required positive pressure ventilation 5.
Adrenal suppression: While cortisol levels remain within normal laboratory ranges during the dysfunction period 6, avoid etomidate in patients with septic shock or known adrenal insufficiency where this transient suppression could be clinically significant.
Cardiovascular stability: Etomidate maintains hemodynamic stability better than propofol, with minimal effect on myocardial metabolism, cardiac output, and peripheral circulation 1. This makes it particularly valuable in hemodynamically unstable patients despite the recent trial data showing slightly higher cardiovascular collapse rates with ketamine 3.